Happy to share our work w Nick Kuhn on identifying spatiotemporal patterns of gene programs in the healing wound is live Cell Stem Cell : cell.com/cell-stem-cell…. A pithy summary:

We report in The Lancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert UroToday.com PCF Science

Researcher Laurent Beziaud at EPFL Life Sciences focused on the role of cancer stem cell (CSC) plasticity in immune evasion following ICB. In mouse breast tumor models, T cell-produced IFNγ increased conversion of non-CSCs to CSCs, which increased chemo- and [...] bit.ly/3J2U5GN

Researchers demonstrated that pristane and its derivatives NJNU-0069 and NJNU-0069-003 induced MHC-II expression in cancer cells to potentiate antigen presentation and immune detection, which increased T cell infiltration and antitumor immunity in [...] bit.ly/3MU0026

💡 Get an in-depth look into T cells in health and disease! Scientists summarize the current understanding of #Tcell development, CD4+ and CD8+ T cell classification, and differentiation in physiological settings. 📚 go.nature.com/447ejYF

New #JITC review: Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA jitc.bmj.com/content/11/6/e… Nick Semenkovich, MD PhD Noah Earland Bruna Pellini, MD Aadel Chaudhuri, MD PhD

Melanoma expert docs @BhatiaS_MD Janice Mehnert, MD @MunTheLoon Siwen Hu-Lieskovan Helen Rizos Jose Lutzky, MD, FACP Inderjit Mehmi Walter J Urba MD, PhD Dr. Brendan Curti ONCODOC elizabeth buchbinder

Join us Sep 6 for a comprehensive overview of clinical management of melanoma, from early stage to IO refractory, non-melanoma skin cancers, irAEs and beyond. Bring your questions and interact with frontline clinical investigators. Society for Immunotherapy of Cancer ACI series. Huntsman Cancer Institute

Two important messages from this prospective randomized study of melanoma w primary resistance to aPD1. 1)combo w aPD1 is still important after prior PD: ORR 9% Ipi, 28% Ipi/Niv 2)Ipi/Niv is active in IO refractory setting, consider sequencing for lower risk dz to reduce toxicity

I am very sorry to lose a dear colleague and friend, the very first and critical member of my lab University of Utah, who made seminal contribution to our research and core services Huntsman Cancer Institute, passed away prematurely from cancer at a young age. RIP Yoko.

Dr. David Kozono presenting updates on Alliance irAEs bio repository trial from Alliance SWOG Cancer Research Network immunotherapeutics committee. Participants can enroll at the time of starting ICI now Elad Sharon @politikaterina Siwen Hu-Lieskovan